In the News

1853 News Items found
Marie-Josée Kravis Quantitative Biology Fellows Corey Weistuch and Sneha Mitra
Learn about the Marie-Josée Kravis Fellowship in Quantitative Biology, a two-year postdoctoral fellowship that aims to build a new generation of skilled quantitative biologists who specialize in cancer.
Gloved hands hold a pipette over two bottles of pink solution.
Finding
Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.
MSK computational biologist Henry Walch
African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.
Mobile Health Unit
MSK’s Mobile Health Unit provides health education, screening, and navigation services to underserved communities in the New York metro area.
Cassidy Cobbs
Cassidy Cobbs is many things: a valued colleague who works at the Sloan Kettering Institute; a doting parent to a pit bull named Mando; a beloved sibling; and a passionate baseball fan, who memorized the stats of former player, Ryne Sandberg, at the age of 5. What Cassidy is not is someone who identifies as either a man or a woman.
Microscopy image showing a quiescent cluster of lung adenocarcinoma tumor cells with low STING expression.
A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.
Dr. Carol Aghajanian
In the Clinic
New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.
A scientist pipetting in a lab
MSK Research Highlights, March 9, 2023
New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.
MSK physician-scientists Michele Sadelain, Isabelle Riviere, and Jae Park
A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.
Daniel Heller
Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.